These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9718319)

  • 1. A potent "fat base" nucleotide inhibitor of IMP dehydrogenase.
    Wang W; Hedstrom L
    Biochemistry; 1998 Aug; 37(34):11949-52. PubMed ID: 9718319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate.
    Wang W; Papov VV; Minakawa N; Matsuda A; Biemann K; Hedstrom L
    Biochemistry; 1996 Jan; 35(1):95-101. PubMed ID: 8555204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid-base catalysis in the chemical mechanism of inosine monophosphate dehydrogenase.
    Markham GD; Bock CL; Schalk-Hihi C
    Biochemistry; 1999 Apr; 38(14):4433-40. PubMed ID: 10194364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.
    Jain J; Almquist SJ; Heiser AD; Shlyakhter D; Leon E; Memmott C; Moody CS; Nimmesgern E; Decker C
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1272-7. PubMed ID: 12183689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
    Ratcliffe AJ
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):595-605. PubMed ID: 17002220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors.
    Sintchak MD; Nimmesgern E
    Immunopharmacology; 2000 May; 47(2-3):163-84. PubMed ID: 10878288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic mechanism of human inosine 5'-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products.
    Wang W; Hedstrom L
    Biochemistry; 1997 Jul; 36(28):8479-83. PubMed ID: 9214292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP dehydrogenase: mechanism of action and inhibition.
    Hedstrom L
    Curr Med Chem; 1999 Jul; 6(7):545-60. PubMed ID: 10390600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory action of polyunsaturated fatty acids on IMP dehydrogenase.
    Mizushina Y; Dairaku I; Yanaka N; Takeuchi T; Ishimaru C; Sugawara F; Yoshida H; Kato N
    Biochimie; 2007 May; 89(5):581-90. PubMed ID: 17383068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent inactivation of Mycobacterium thermoresistibile inosine-5'-monophosphate dehydrogenase (IMPDH).
    Trapero A; Pacitto A; Chan DS; Abell C; Blundell TL; Ascher DB; Coyne AG
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126792. PubMed ID: 31757668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis.
    Fleming MA; Chambers SP; Connelly PR; Nimmesgern E; Fox T; Bruzzese FJ; Hoe ST; Fulghum JR; Livingston DJ; Stuver CM; Sintchak MD; Wilson KP; Thomson JA
    Biochemistry; 1996 Jun; 35(22):6990-7. PubMed ID: 8679523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-dimensional pharmacophore model for IMPDH inhibitors.
    Yang N; Wang J; Li J; Wang QH; Wang Y; Cheng MS
    Chem Biol Drug Des; 2011 Jul; 78(1):175-82. PubMed ID: 21507206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate.
    Pal S; Bera B; Nair V
    Bioorg Med Chem; 2002 Nov; 10(11):3615-8. PubMed ID: 12213477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The practical synthesis of a methylenebisphosphonate analogue of benzamide adenine dinucleotide: inhibition of human inosine monophosphate dehydrogenase (type I and II).
    Pankiewicz KW; Lesiak K; Zatorski A; Goldstein BM; Carr SF; Sochacki M; Majumdar A; Seidman M; Watanabe KA
    J Med Chem; 1997 Apr; 40(8):1287-91. PubMed ID: 9111303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.
    Felczak K; Chen L; Wilson D; Williams J; Vince R; Petrelli R; Jayaram HN; Kusumanchi P; Kumar M; Pankiewicz KW
    Bioorg Med Chem; 2011 Mar; 19(5):1594-605. PubMed ID: 21324702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, conformational analysis, and biological activity of new analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) as IMP dehydrogenase inhibitors.
    Franchetti P; Cappellacci L; Pasqualini M; Petrelli R; Jayaprakasan V; Jayaram HN; Boyd DB; Jain MD; Grifantini M
    Bioorg Med Chem; 2005 Mar; 13(6):2045-53. PubMed ID: 15727858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors.
    Cholewiński G; Iwaszkiewicz-Grześ D; Prejs M; Głowacka A; Dzierzbicka K
    J Enzyme Inhib Med Chem; 2015; 30(4):550-63. PubMed ID: 25198892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monovalent cation activation in Escherichia coli inosine 5'-monophosphate dehydrogenase.
    Kerr KM; Cahoon M; Bosco DA; Hedstrom L
    Arch Biochem Biophys; 2000 Mar; 375(1):131-7. PubMed ID: 10683258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG; Boosalis M; Malek K; Waraska K
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
    Chen L; Pankiewicz KW
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):403-12. PubMed ID: 17659481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.